KISS1R activation
Kisspeptin-10 binds its receptor on GnRH-regulating neurons in the hypothalamus.
Active 10-Amino-Acid Fragment • KISS1R / GPR54 Agonist
Kisspeptin-10 is the active C-terminal fragment of kisspeptin. It stimulates hypothalamic GnRH signaling and can acutely increase LH, FSH, and downstream sex-hormone activity in responsive individuals.
Kisspeptin-10 is a synthetic version of the active 10-amino-acid C-terminal fragment of kisspeptin-54. It retains activity at the kisspeptin receptor, KISS1R (also called GPR54).
Hypothalamic kisspeptin neurons help regulate the hypothalamic-pituitary-gonadal axis. KISS1R activation stimulates GnRH neurons; GnRH then signals the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In men, LH supports testicular testosterone production, while FSH contributes to Sertoli-cell function and sperm production.
This upstream action differs from hCG, which acts at the testicular LH receptor, and testosterone replacement, which supplies hormone externally and usually suppresses endogenous gonadotropins. It also differs from enclomiphene's estrogen-receptor blockade. Human studies confirm acute hormone signaling, but repeated-cycle, fertility, and long-term outcomes remain uncertain.
Kisspeptin-10 binds its receptor on GnRH-regulating neurons in the hypothalamus.
The hypothalamus sends a gonadotropin-releasing hormone signal to the pituitary.
The pituitary releases LH and FSH; their response depends on the rest of the reproductive axis.
In responsive men, this can increase testicular testosterone signaling without directly replacing testosterone.
Human studies show acute signaling and sexual-processing effects; durable testosterone or fertility benefits have not been established.
Acute LH increases can be followed by testosterone changes in some men; this is not equivalent to a proven long-term testosterone protocol.
LH and FSH engage pathways relevant to testicular function and spermatogenesis, but improved sperm count or fertility is not guaranteed.
A randomized study in men with low sexual desire reported changes in sexual-processing activity and arousal measures versus placebo.
Because it does not supply testosterone directly, kisspeptin differs from replacement therapy; repeated-cycle recovery is still unproven.
Sign in or create a free account to view this content.
Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.
Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.
Swirl or roll the vial until the contents dissolve; do not shake.
Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.
These pairings target different points in hormone or sexual-response pathways. No combination below has an established community dosing protocol.
Both may increase gonadotropin signaling by different mechanisms. Combined response and feedback effects need lab monitoring.
Kisspeptin acts upstream through GnRH and pituitary LH/FSH; hCG acts at the testicular LH receptor. Combining them can obscure which signal changed results.
The former addresses reproductive signaling; the latter is used for growth-hormone signaling. Their combined outcomes have not been established.
Kisspeptin targets the reproductive hormone axis; PT-141 acts through melanocortin signaling. Their combined sexual effects have not been established.
Kisspeptin-10 is not FDA approved. Short human studies establish acute biological activity, but do not validate long-term community SubQ use.
We like kisspeptin for the possibility of supporting natural testosterone and fertility signaling. It works upstream of LH and FSH, so it feels like a more measured option to explore than moving straight to testosterone replacement when preserving the HPG axis matters. We also expect more modest results than stronger hormonal interventions.
We have seen people report subtle, sustainable benefits and others who barely notice a difference. For us, bloodwork is essential: establish a baseline, then check whether LH, FSH, testosterone, and estradiol actually move. We give it a B because the acute human signal is real, while the community schedule and lasting outcomes still need better evidence.
Peptide Protocols
Send us a message and we’ll reply to the email address you provide.